The estimated Net Worth of Charles Garner is at least 10.5 千$ dollars as of 5 June 2015. Charles Garner owns over 2,000 units of Recro Pharma Inc stock worth over 10,450$ and over the last 11 years Charles sold REPH stock worth over 0$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Garner REPH stock SEC Form 4 insiders trading
Charles has made over 2 trades of the Recro Pharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Charles bought 2,000 units of REPH stock worth 17,000$ on 5 June 2015.
The largest trade Charles's ever made was buying 3,000 units of Recro Pharma Inc stock on 15 May 2014 worth over 20,070$. On average, Charles trades about 1,000 units every 77 days since 2014. As of 5 June 2015 Charles still owns at least 5,000 units of Recro Pharma Inc stock.
You can see the complete history of Charles Garner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Charles Garner's mailing address?
Charles's mailing address filed with the SEC is 490 LAPP ROAD, , MALVERN, PA, 19355.
Insiders trading at Recro Pharma Inc
Over the last 11 years, insiders at Recro Pharma Inc have traded over 25,533,136$ worth of Recro Pharma Inc stock and bought 3,055,820 units worth 22,429,197$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Investment Company, Inc. Awm、James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of 151,953$. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth 1,004$.
What does Recro Pharma Inc do?
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
What does Recro Pharma Inc's logo look like?
Complete history of Charles Garner stock trades at Recro Pharma Inc
Recro Pharma Inc executives and stock owners
Recro Pharma Inc executives and other stock owners filed with the SEC include:
-
Geraldine Henwood,
President, Chief Executive Officer, Director -
Ryan Lake,
Chief Financial Officer -
William Ashton,
Independent Director -
Wayne Weisman,
Independent Chairman of the Board -
Winston Churchill,
Independent Director -
Michael Berelowitz,
Independent Director -
Ryan D. Lake,
Chief Financial Officer -
Bryan Reasons,
Independent Director -
J. David Enloe Jr.,
Pres, CEO & Director -
Argot Partners,
IR Contact Officer -
Tim Bourque,
VP of Operations & Site Head of San Diego -
David Smithwick B.S.,
VP of Operations & Site Head of Gainesville -
Richard Sidwell Ph.D.,
VP & Chief Scientific Officer -
Marshall Rizzo M.B.A.,
Sr. VP & GM -
Randall J. Mack,
Sr. VP of Devel. -
Erica Raether M.A.,
VP of People, Culture & ESG -
William Hirschman,
VP of Sales & Marketing -
Matthew McKendry,
Director of Accounting -
Laura L. Parks,
Director -
Karen Flynn,
Director -
Vitalife Partners Ii Lp Scp,
10% owner -
Donna Nichols,
CAO/Controller -
Stewart Mc Callum,
Chief Medical Officer -
Randall Mack,
Senior VP, Development -
Fred Graff,
Chief Commercial Officer -
Capital Management, Llc Sto...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Vitalife Partners (Israel) ...,
10% owner -
Alfred Altomari,
Director -
Healthcare Master Fund Ltd ...,
-
Diane Myers,
Senior VP-Reg./Quality -
Jyrki Mattila,
Executive VP, Business Dev. -
Michael Celano,
Chief Financial Officer -
Arnaud Ajdler,
Director -
Abraham Ludomirski,
Director -
Charles Garner,
CFO and Chief Business Officer -
J David Jr Enloe,
Chief Executive Officer -
James Charles Miller,
Director -
Investment Company, Inc. Awm,
10% owner